Get started
Author

José Dinis

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
2018 · Ezra E W Cohen, Denis Soulières, et al. · The Lancet · 1,736
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE
2011 · Steven Grunberg, Daniel Chua, et al. · Journal of Clinical Oncology · 213
Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial
2017 · E.E. Cohen, K.J. Harrington, et al. · Annals of Oncology · 91
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
2014 · Vassiliki Saloura, Ezra E. W. Cohen, et al. · Cancer Chemotherapy and Pharmacology · 89
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
2025 · Robert Haddad, Jérôme Fayette, et al. · JAMA · 62
Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
2014 · Ramon Andrade de Mello, Sandra Gerós, et al. · PLoS ONE · 53
PDF
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
2019 · Barbara Burtness, Robert Haddad, et al. · JAMA Oncology · 45
PDF
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040
2020 · Kevin J Harrington, Denis Soulières, et al. · JNCI Journal of the National Cancer Institute · 38
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Jérôme Fayette, Lisa Licitra, et al. · Clinical Cancer Research · 34
PDF
Genotypes at the APOE and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin
2004 · Mónica Santos, Maria do Carmo Costa, et al. · Multiple Sclerosis Journal · 31
Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
2018 · Denis Soulieres, Ezra Cohen, et al. · Cancer Research · 29
Abstract CT009: IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
2024 · Deborah J. Wong, Jérôme Fayette, et al. · Cancer Research · 24
Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors
2010 · Mara Silva, Isabel Veiga, et al. · BMC Medicine · 22
PDF
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence
2023 · K.J. Harrington, E.E.W. Cohen, et al. · Oral Oncology · 19
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
2018 · Ezra E.W. Cohen, Denis Soulieres, et al. · Journal of Clinical Oncology · 16
Hereditary gastrointestinal stromal tumors sharing the KIT Exon 17 germline mutation p.Asp820Tyr develop through different cytogenetic progression pathways
2009 · Isabel Veiga, Mara Silva, et al. · Genes Chromosomes and Cancer · 16
A whole genome screen for association with multiple sclerosis in Portuguese patients
2003 · M. Santos, J. Pinto-Basto, et al. · Journal of Neuroimmunology · 14
PDF
A 10-year review of primary major salivary gland cancers
2020 · Andreia Cruz, Helena Magalhães, et al. · ecancermedicalscience · 12
PDF
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
2017 · Barbara Burtness, Robert I. Haddad, et al. · Journal of Clinical Oncology · 12
Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial
2024 · Beatrice Mainoli, Joana Assis, et al. · Acta Oncologica · 7
Atlas of Cancer Mortality in Portugal and Spain (2003–2012)
2021 · Fernandez-Navarro, Pablo, Roquette, Rita, et al. · Instituto de Salud Carlos III (Spain) eBooks · 7
Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial
2018 · C. Le Tourneau, E.E.W. Cohen, et al. · Annals of Oncology · 7
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
2019 · Kevin J. Harrington, Ezra E.W. Cohen, et al. · Journal of Clinical Oncology · 4
Perfil da doença oncológica em Portugal racional, objectivos e metodologia - estudo perfil.
2008 · Ana Macedo, Sofia Andrade, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 4
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
2013 · Vassiliki Saloura, Ezra E.W. Cohen, et al. · Journal of Clinical Oncology · 3
Works count: 53
Citation count: 4,371
H-index: 16
I10-index: 21
Year
Topic
Type